论文部分内容阅读
德国著名滑冰运动员佩希施泰因(Pechstein)血液筛检结果呈现异常,超出了国际滑联规定的参数范围,国际滑联纪律委员会对其处以两年禁赛。2009年7月佩希施泰因向体育仲裁院(CAS)提出了上诉。案件的争议点是反兴奋剂检测的新技术——血液样本特征记录,亦称生物护照的可信度、可靠性与合法性。最终CAS仲裁庭认定:运动员血液值异常不能合理解释为任何先天性或后天发育异常,其必定来自运动员人为非法操纵血液,运动员败诉。生物护照反兴奋剂处罚第一案,具有深刻的意义,必将影响全球的反兴奋剂斗争。
Germany’s famous skater Pechstein blood screening results showed abnormalities beyond the scope of the ISU’s parameters, the ISU Disciplinary Committee imposed a two-year suspension. July 2009 Pheuschtein filed an appeal with Sport Court of Arbitration (CAS). The controversial point of the case is the anti-doping test of new technology - blood sample records, also known as biological passport reliability, reliability and legitimacy. The final arbitration court CAS found that: abnormal blood flow of athletes can not reasonably be interpreted as any congenital or acquired developmental abnormalities, it must come from the athletes artificially manipulated the blood, athletes lose. The first case of bio-passport anti-doping punishment is of profound significance and will surely affect the global fight against doping.